Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P35544

UPID:
RS30_HUMAN

ALTERNATIVE NAMES:
FAU ubiquitin like and ribosomal protein S30 fusion

ALTERNATIVE UPACC:
P62861; P35544; Q05472; Q95261; Q9H5V4

BACKGROUND:
P35544 is a protein of significant interest due to its potential involvement in critical biological pathways. Research is focused on elucidating its functions, which are believed to be pivotal in maintaining cellular homeostasis. The protein's unique characteristics and its role in cellular processes underscore the importance of detailed study.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of this protein holds the promise of unveiling new therapeutic approaches. The protein's central role in cellular functions suggests that it could be a key target in developing treatments for diseases, thereby contributing to advancements in medical science.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.